S-1: Yield10 Bioscience Eyes $7 Million Raise Through Unit Offering

Yield10 Bioscience is seeking to raise capital through an offering of units consisting of common stock or pre-funded warrants and common warrants.

Summary

• Yield10 Bioscience is offering units, each consisting of one share of common stock and one common warrant, or pre-funded warrants and common warrants, to raise up to $7 million.
• The offering includes common warrants exercisable for one share of common stock at a price to be determined, expiring five years from issuance.
• Pre-funded warrants are offered as an alternative for purchasers who would exceed a 4.99% ownership threshold, with an exercise price of $0.001 per share.
• The company intends to use the net proceeds for general corporate purposes, including working capital.
• The offering is on a reasonable best-efforts basis, with no minimum amount required to be sold.
• A reverse stock split of 1:24 was effected on May 2, 2024.
• The company's stock is traded on The Nasdaq Capital Market under the symbol YTEN.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments in regulatory approvals and technology, the company's financial situation and need for additional funding raise concerns.

Positives

• The company has received regulatory approval from USDA-APHIS for two engineered Camelina lines.
• The company has successfully developed commercial-quality Camelina varieties containing an herbicide tolerant (HT) trait for glufosinate tolerance alone or as a stacked herbicide tolerant (stacked HT) trait for glufosinate tolerance in combination with tolerance to Group 2 herbicides, specifically including tolerance to both imidazolinones and sulfonylureas.
• The company believes that the favorable regulatory path for engineered Camelina in the U.S. and bodes well for the accelerated development of this crop using Yield10s advanced technology, gene traits and capabilities.

Negatives

• The offering is on a reasonable best-efforts basis, with no minimum amount required to be sold, which may significantly reduce the amount of proceeds received by the company.
• The company may have insufficient capital to implement its business plans, potentially resulting in greater operating losses.
• Investors will experience immediate and substantial dilution as a result of this offering.
• There is no public market for the common warrants or pre-funded warrants being offered.
• The company had cash, cash equivalents and short-term investments of $1.1 million as of December 31, 2023, which is expected to provide funding for operations only into the second quarter of 2024.

Risks

• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received.
• Management will have broad discretion as to the use of the proceeds from this offering and may not use the proceeds effectively.
• The company may not receive any additional funds upon the exercise of the common warrants.
• Investors will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.
• There is no public market for the common warrants or pre-funded warrants being offered.
• If the company is unable to raise substantial additional funds in the near term, it will be unable to continue to operate its business and remain a going concern.
• There can be no assurance that the company will be able to comply with the continued listing standards of The Nasdaq Capital Market.
• The company has completed a reverse stock split on May 2, 2024 in an effort to regain compliance with Nasdaq listing rules, and we cannot predict the effect that such reverse stock split will have on the market price for shares of our common stock.

Future Outlook

The company plans to continue development work with spring E3902 stack HT Camelina and winter stacked HT Camelina during 2024, and aims for first commercial-scale production of EPA8 oil in 2026.

Industry Context

The document highlights Yield10's focus on Camelina sativa as a platform crop for omega-3 fatty acid production and biofuel feedstock, addressing the growing demand for sustainable alternatives to traditional sources like fish oil and non-food oilseed production for biofuels.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• However, it positions Yield10 as a leader in Camelina seed genetics and advanced trait technology development, particularly in herbicide tolerance and omega-3 production.
• The company aims to establish a closed-loop production system for omega-3 oil, targeting the aquafeed market, similar to vertically integrated models used by some aquaculture companies.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's ability to execute its business plan and achieve profitability will impact stakeholders.
• The success of the Camelina platform could benefit growers, aquafeed producers, and consumers seeking sustainable products.

Next Steps

• The company plans to continue development work with spring E3902 stack HT Camelina and winter stacked HT Camelina during 2024.
• The company plans to bring both Omega-3 Camelina products forward in development with 2026 being the target for the first commercial-scale production of the EPA8 oil.
• The company plans to file for regulatory approval for the use of its omega-3 oils in aquafeed formulations in Chile this year.
• The company plans to launch a business focused on the production of EPA and EPA+DHA oils based on the Omega-3 Camelina traits developed over the last 10 years by Rothamsted in the U.K.
• The company will continue its focus on developing elite Camelina varieties with herbicide tolerance, disease resistance, higher yield and oil content, with the intent to breed Rothamsteds omega-3 product trait into this germplasm in the future.
• The company has agreed to seek stockholder approval of the issuance of the shares of our common stock underlying the New Warrants at our 2024 Annual Meeting of Stockholders on June 7, 2024.

Key Dates

Keywords

Yield10 Bioscience, common stock, pre-funded warrants, common warrants, offering, Camelina, capital raise, biofuels, omega-3, herbicide tolerance